Sugi Predict

Sugi Predict / Compounds / SCHEMBL70271

SCHEMBL70271

SCHEMBL70271

O=C(O)CCc1cccc(CCC(=O)O)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.74
▸ FFAR1 O14842 12/20 0.68
▸ PTPRB P23467 1/20 0.67
▸ CDC25A P30304 1/20 0.67
▸ CDC25B P30305 1/20 0.67
▸ PTEN P60484 1/20 0.67
▸ PTPMT1 Q8WUK0 1/20 0.67
▸ HDAC3 O15379 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ ADRA1A P35348 1/20 0.56
▸ HDAC4 P56524 1/20 0.56
▸ SLC6A3 Q01959 1/20 0.56
▸ HDAC1 Q13547 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ HDAC7 Q8WUI4 1/20 0.56
▸ HDAC2 Q92769 1/20 0.56
▸ HDAC10 Q969S8 1/20 0.56
▸ HDAC11 Q96DB2 1/20 0.56
▸ HDAC8 Q9BY41 1/20 0.56
▸ HDAC6 Q9UBN7 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10982620 0.98 KEAP1 (0.71) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL8435278 0.94 FFAR1 (0.80) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL4407150 0.92 KEAP1 (0.63) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL30638471 0.92 KEAP1 (0.63) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL9051375 0.92 FFAR1 (0.64) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL8614478 0.90 KEAP1 (0.67) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL19333997 0.90 KEAP1 (0.61) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL3242805 0.90 KEAP1 (0.61) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL1206832 0.90 KEAP1 (0.61) KEAP1FFAR1PTPRBCDC25ACDC25B
SCHEMBL31273986 0.90 KEAP1 (0.61) KEAP1FFAR1PTPRBCDC25ACDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024044062-A1 THERMOPLASTIC PARTICULATES AND METHOD TO MAKE THEM Jabil Inc. (US) 2024-02-29 — — WO claimed
US-20170365729-A1 NANOWIRE COMPOSITE STRUCTURE AND METHODS OF FORMING THE SAME, SENSING DEVICE AND METHODS OF FORMING THE SAME AND PROTECTIVE STRUCTURES OF A NANOWIRE NATIONAL TSING HUA UNIVERSITY (TW) 2017-12-21 — — US claimed
EP-0894109-A1 PROCESS FOR THE PREPARATION OF POLYANHYDRIDES Abbott Laboratories (US) 1999-02-03 — — EP claimed
WO-1997039048-A1 PROCESS FOR THE PREPARATION OF POLYANHYDRIDES ABBOTT LABORATORIES (US) 1997-10-23 — — WO claimed
EP-0260415-B1 Synthesis and application of high molecular weight polyanhydrides MASSACHUSETTS INST TECHNOLOGY (US) 1996-11-27 — — EP claimed
EP-0605536-A4 FATTY ACID TERMINATED POLYANHYDRIDES. SCIOS NOVA INC (US) 1994-07-20 — — EP claimed
EP-0605536-A1 FATTY ACID TERMINATED POLYANHYDRIDES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1994-07-13 — — EP claimed
WO-1993005096-A1 FATTY ACID TERMINATED POLYANHYDRIDES NOVA PHARMACEUTICAL CORPORATION (US) 1993-03-18 — — WO claimed
US-4491665-A QUARTERNIZATION, ESTERIFICATION BURROUGHS WELLCOME CO. (US) 1985-01-01 — — US claimed
EP-3660040-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-06-18 — — EP disclosed
US-20250025854-A1 EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF ExxonMobil Technology and Engineering Company 2025-01-23 — — US disclosed
US-20250025855-A1 EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF ExxonMobil Technology and Engineering Company 2025-01-23 — — US disclosed
EP-3666792-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-12-18 — — EP disclosed
US-12161990-B2 EMM-41 composition, methods of making and uses thereof ExxonMobil Technology and Engineering Company (US) 2024-12-10 — — US disclosed
CN-1085911-A Peptide compounds HAFSLUND NYCOMED AS (NO) 1994-04-27 — — CN disclosed
WO-1993005096-A1 FATTY ACID TERMINATED POLYANHYDRIDES NOVA PHARMACEUTICAL CORPORATION (US) 1993-03-18 — — WO disclosed
US-4491665-A QUARTERNIZATION, ESTERIFICATION BURROUGHS WELLCOME CO. (US) 1985-01-01 — — US disclosed
US-4192877-A BIS(POLYALKOXYBENZYL)-TETRAHYDROISOQUINOLIUM ALKYL M- OR P- PHENYLENE DIPROPIONATE SALT MASSACHUSETTS GENERAL HOSPITAL (US) 1980-03-11 — — US disclosed
US-4191776-A ANTITHROMBOTICS, ANTICHOLESTEREMICS, ANTICOAGULANTS BOEHRINGER INGELHEIM GMBH (DE) 1980-03-04 — — US disclosed
US-3993683-A ANTITHROMBOTIC, ANTICHOLESTEREMICS, ANTICOAGULANTS BOEHRINGER INGELHEIM GMBH (DT) 1976-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250025855-A1 EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF CD14, CD68, MASP2 KEAP1 4581/4885FFAR1 4600/4885PTPRB 3009/4885
US-12161990-B2 EMM-41 composition, methods of making and uses thereof CD14, CD68, MASP2 KEAP1 4581/4885FFAR1 4600/4885PTPRB 3009/4885
US-20250025854-A1 EMM-41 COMPOSITION, METHODS OF MAKING AND USES THEREOF CD14, CD68, MASP2 KEAP1 4581/4885FFAR1 4600/4885PTPRB 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.